Terms: = Leukemia AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734 AND Clinical Outcome
1216 results:
1. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
2. Incidence, risk factors, and outcome of asymptomatic central nervous system involvement in adult patients with acute myeloid leukemia.
Virijevic M; Kraguljac-Kurtovic N; Mitrovic M; Jakovic L; Bukumuric Z; Pantic N; Sabljic N; Pravdic Z; Cvetkovic M; Knezevic V; Dragovic-Ivancevic T; Djunić I; Rajic J; Milosevic V; Todorovic-Balint M; Vidovic A; Suvajdzic-Vukovic N
Hematol Oncol; 2024 Mar; 42(2):e3253. PubMed ID: 38536200
[TBL] [Abstract] [Full Text] [Related]
3. clinical Analysis of Pediatric Acute Megakaryocytic leukemia With CBFA2T3-GLIS2 Fusion Gene.
Du Y; Yang L; Qi S; Chen Z; Sun M; Wu M; Wu B; Tao F; Xiong H
J Pediatr Hematol Oncol; 2024 Mar; 46(2):96-103. PubMed ID: 38315896
[TBL] [Abstract] [Full Text] [Related]
4. A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid leukemia.
Zhai Y; Shen H; Wei H
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254953
[TBL] [Abstract] [Full Text] [Related]
5. Patient-Specific Measurable Residual Disease Markers Predict outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
[TBL] [Abstract] [Full Text] [Related]
6. Validation of genes for H-ARS severity prediction in leukemia patients - interspecies comparison, challenges, and promises.
Schwanke D; Valente M; Ostheim P; Schüle S; Bobyk L; Drouet M; Riccobono D; Magné N; Daguenet E; Stewart SJ; Muhtadi R; Port M; Abend M
Int J Radiat Biol; 2024; 100(4):527-540. PubMed ID: 38227483
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature.
Abdelbaky SB; Giacopelli B; Rabe KG; Yamaguchi K; Wu YZ; Yan H; Shanafelt TD; Parikh SA; Ding W; Hampel PJ; Brown S; Cerhan JR; Vachon CM; Kay NE; Hanson CA; Parker AS; Braggio E; Slager SL; Oakes CC
Blood; 2024 Apr; 143(17):1752-1757. PubMed ID: 38194687
[TBL] [Abstract] [Full Text] [Related]
8. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.
Zhang C; Stelloo E; Barrans S; Cucco F; Jiang D; Tzioni MM; Chen Z; Li Y; Swennenhuis JF; Makker J; Rásó-Barnett L; Liu H; El-Daly H; Soilleux E; Shah N; Nagumantry SK; Kyaw M; Prahladan MP; Tooze R; Westhead DR; Feitsma H; Davies AJ; Burton C; Johnson PWM; Du MQ
Leukemia; 2024 Mar; 38(3):621-629. PubMed ID: 38184753
[TBL] [Abstract] [Full Text] [Related]
9. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
10. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
Kubota H; Ueno H; Tasaka K; Isobe T; Saida S; Kato I; Umeda K; Hiwatari M; Hasegawa D; Imamura T; Kakiuchi N; Nannya Y; Ogawa S; Hiramatsu H; Takita J
Blood Adv; 2024 Mar; 8(5):1258-1271. PubMed ID: 38127276
[TBL] [Abstract] [Full Text] [Related]
11. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
12. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Maura F; Boyle EM; Coffey D; Maclachlan K; Gagler D; Diamond B; Ghamlouch H; Blaney P; Ziccheddu B; Cirrincione A; Chojnacka M; Wang Y; Siegel A; Hoffman JE; Kazandjian D; Hassoun H; Guzman E; Mailankody S; Shah UA; Tan C; Hultcrantz M; Scordo M; Shah GL; Landau H; Chung DJ; Giralt S; Zhang Y; Arbini A; Gao Q; Roshal M; Dogan A; Lesokhin AM; Davies FE; Usmani SZ; Korde N; Morgan GJ; Landgren O
Nat Cancer; 2023 Dec; 4(12):1660-1674. PubMed ID: 37945755
[TBL] [Abstract] [Full Text] [Related]
13. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
Zhong F; Yang Y; Yao F; Liu J; Yu X; Wang XL; Huang B; Wang XZ
Aging (Albany NY); 2023 Oct; 15(20):11217-11226. PubMed ID: 37845004
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA CRNDE is downregulated and associated with poor prognostic markers in chronic lymphocytic leukemia.
Shehata AMF; Gohar SF; Muharram NM; Soliman SS; Shalaby HM; Kamal Eldin SM; El-Bassal FI
Int J Lab Hematol; 2024 Feb; 46(1):107-112. PubMed ID: 37814899
[TBL] [Abstract] [Full Text] [Related]
15. Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract] [Full Text] [Related]
16. clinical outcomes of Patients with Chronic Myeloid leukemia and COVID-19 Infection-A Single Center Survey.
Ćojbašić I; Golubović I; Ćojbašić Ž
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763683
[No Abstract] [Full Text] [Related]
17. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C; Valk PJM; Blijlevens NMA; Cornelissen JJ; Dinmohamed AG; Geelen I; Hoogendoorn M; Janssen JJWM; Daenen LGM; Reijden BAV; Westerweel PE
Eur J Haematol; 2023 Dec; 111(6):938-945. PubMed ID: 37731314
[TBL] [Abstract] [Full Text] [Related]
18. Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Donnette M; Hamimed M; Ciccolini J; Sicard G; Correard F; Farnault L; Ouafik L; Venton G; Fanciullino R
Br J Haematol; 2023 Nov; 203(4):625-636. PubMed ID: 37691342
[TBL] [Abstract] [Full Text] [Related]
19. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions.
de Mendoza C; Rando A; Miró E; Pena MJ; Rodríguez-Avial I; Ortega D; González-Praetorius A; Reina G; Pintos I; Pozuelo MJ; Soriano V;
J Clin Virol; 2023 Oct; 167():105578. PubMed ID: 37660433
[TBL] [Abstract] [Full Text] [Related]
20. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients.
Jandial A; Lad D; Jain A; Khadwal A; Singh C; Prakash G; Suri V; Sreedharanunni S; Sachdeva MUS; Ray P; Varma N; Varma S; Malhotra P
Transpl Infect Dis; 2023 Oct; 25(5):e14123. PubMed ID: 37573150
[TBL] [Abstract] [Full Text] [Related]
[Next]
